MolPharm Over 1500 Individual Drug Articles!

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on September 24, 2004; DOI: 10.1124/mol.104.003806


0026-895X/04/6606-1719-1726$20.00
Mol Pharmacol 66:1719-1726, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.003806v1
66/6/1719    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Börner, C.
Right arrow Articles by Höllt, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Börner, C.
Right arrow Articles by Höllt, V.

Transcriptional Regulation of the Human µ-Opioid Receptor Gene by Interleukin-6

Christine Börner, Jürgen Kraus, Helmut Schröder, Hermann Ammer1, and Volker Höllt

Department of Pharmacology and Toxicology, University of Magdeburg, Magdeburg, Germany

Inflammatory pain is counteracted by a number of physiological processes. For example, opioid receptors, which are present on peripheral terminals of sensory neurons, are activated by endogenous opioids, which are released from immune cells migrating to the inflamed tissue. Earlier data demonstrated that interleukin-6 contributes to such inflammation-induced analgesia. In this report, we demonstrated that interleukin-6 strongly induces µ-opioid receptor mRNA in the human neuroblastoma cell line SH SY5Y, whereas {delta}-opioid receptor mRNA levels are not influenced. The mRNA increase in these cells is followed by an increase in µ-opioid receptor-specific binding. Using transcription factor decoy oligonucleotides, direct evidence was provided that the up-regulation of µ-opioid receptor mRNA in intact cells is dependent on the transcription factors signal transducers and activators of transcription 1 (STAT1) and STAT3, whereas other transcription factors, such as activator protein-1, nuclear factor (NF)-{kappa}B, or NF-interleukin-6 are not involved. STAT1 and STAT3 bound to a site located at nucleotide -1583 on the promoter of the human µ-opioid receptor gene, as shown by transient transfection experiments, electrophoretic mobility shift assays, and transcription factor decoy oligonucleotides. A mutation analysis of the 5'-TTCATGGAA-3' STAT1/3 element (palindrome underlined) was performed to determine nucleotide residues that are necessary for the binding of STAT1 and STAT3. It suggested that only the palindromic half sides and the two adjacent central nucleotides are required. Neither mutation of the nucleotides outside the palindrome nor mutation of the central nucleotide affected STAT1/3 binding.


Received June 10, 2004; accepted September 21, 2004

Address correspondence to: Dr. Jürgen Kraus, Department of Pharmacology and Toxicology, University of Magdeburg, 44 Leipziger Strasse, 39120 Magdeburg, Germany. E-mail: juergen.kraus{at}medizin.uni-magdeburg.de




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
C. Borner, A. Bedini, V. Hollt, and J. Kraus
Analysis of Promoter Regions Regulating Basal and Interleukin-4-Inducible Expression of the Human CB1 Receptor Gene in T Lymphocytes
Mol. Pharmacol., March 1, 2008; 73(3): 1013 - 1019.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
S. L. Chang, J. A. Beltran, and S. Swarup
Expression of the Mu Opioid Receptor in the Human Immunodeficiency Virus Type 1 Transgenic Rat Model
J. Virol., August 15, 2007; 81(16): 8406 - 8411.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
C. Borner, V. Hollt, W. Sebald, and J. Kraus
Transcriptional regulation of the cannabinoid receptor type 1 gene in T cells by cannabinoids
J. Leukoc. Biol., January 1, 2007; 81(1): 336 - 343.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
S. Matsuzaki, M. Canis, J.-L. Pouly, R. Botchorishvili, P.J. Dechelotte, and G. Mage
Both GnRH agonist and continuous oral progestin treatments reduce the expression of the tyrosine kinase receptor B and mu-opioid receptor in deep infiltrating endometriosis
Hum. Reprod., January 1, 2007; 22(1): 124 - 128.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. Borner, V. Hollt, and J. Kraus
Cannabinoid Receptor Type 2 Agonists Induce Transcription of the {micro}-Opioid Receptor Gene in Jurkat T Cells
Mol. Pharmacol., April 1, 2006; 69(4): 1486 - 1491.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics